Amyotrophic Lateral Sclerosis
Conditions
Keywords
amyotrophic lateral sclerosis, stress granules, HSPB8, protein quality control, colchicine, ALSFRS-r, survival, safety
Brief summary
The study evaluates the effects of two different Colchicine doses (0.01mg/kg/day or 0.005 mg/kg/day) compared to placebo in Amyotrophic Lateral Sclerosis (ALS) patients. Disease progression as defined by changes in ALSFRS-r is the primary outcome measure. Other measures of clinical progression and survival, together with safety and tolerability of Colchicine in ALS patients will be assessed.
Detailed description
Recent evidence supports the disruption of the ubiquitin-proteasome-system and autophagy as central events in ALS. ALS is characterized by the presence of misfolded proteins prone to oligomerize into aggregates, which exert a toxic effect by affecting several intracellular functions. Heat shock protein B8 (HSPB8) recognizes and promotes the autophagy-mediated removal of misfolded mutant SOD1 and TDP-43 fragments from ALS motor neurons (MNs). Moreover, HSPB8-BAG3-HSP70 maintains the so called granulostasis, a surveillance mechanism that avoids the conversion of dynamic stress granules (SGs) into aggregation-prone assemblies, which are a hallmark of ALS. Colchicine enhances the expression of HSPB8 and of several autophagy players while blocking TDP-43 accumulation in neurons. Moreover, given the cross-talk between infalmmation and autophagy, the well-known antinflammatory action of Cochicine may contribute to cell homeostasis. Based on these premises, this is a phase II randomized, double-blind, placebo-controlled, multicenter (9 MND Centres in Italy: 2 centres in Milan, Pavia, Turin, Modena, Padua, Rome, Naples, Bari), clinical trial to test efficacy of Colchicine in ALS.
Interventions
Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
DRUGPlacebo Oral Tablet
Corresponding tablets for 30 weeks
Sponsors
University of Modena and Reggio Emilia
University of Turin, Italy
Istituto Auxologico Italiano
IRCCS National Neurological Institute C. Mondino Foundation
University of Bari
IRCCS San Raffaele
University of Padova
University of Milan
Istituto Di Ricerche Farmacologiche Mario Negri
University of Campania Luigi Vanvitelli
Catholic University of the Sacred Heart
Azienda Ospedaliero-Universitaria di Modena
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
placebo will be unrecognizable from active treatment (both in tablets)
Intervention model description
Three arms of 18 patients each; in two arms two colchicine dosages will be tested compared to placebo in the control arm. The three arms will undergo treatment vs placebo in parallel
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with a laboratory supported, clinically probable or definite amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks, 2000) * Sporadic ALS * ALS phenotypes: classic or bulbar * Female or male patients aged between 18 and 80 years old * Disease duration from symptoms onset no longer than 18 months at the screening visit * Patients treated with a stable dose of Riluzole (100 mg/day) for at least 30 days prior to screening * Patients with a weight \> 50 kg and a BMI ≥18 * Patients with a FVC (Forced Vital Capacity) equal or more than 65 % predicted normal value for gender, height, and age at the screening visit Patients able and willing to comply with study procedures as per protocol * Patients able to understand, and capable of providing informed consent at screening visit prior to any protocol-specific procedures * Use of highly effective contraception
Exclusion criteria
* Prior use of Colchicine * Prior allergy/sensitivity to Colchicine * Receiving Colchicine or other anti-inflammatory drugs (such as corticosteroids, methotrexate, anti-neoplastic, Interleukin 1-1b antagonist, Tumor necrosis factor-alpha inhibitor) * Receiving food or co-medications such as strong-moderate cytochrome P450 3A4 inhibitors that will result in elevated plasma level of Colchicine * Inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or chronic infections (HIV, hepatitis B or C infection) or significant history of malignancy * Severe renal (eGFR\< 30ml/min/1.73m2), or liver failure or liver aminotransferase (ALT/AST \> 2x Upper limit of normal), * Existing blood dyscrasia (e.g., myelodysplasia) * White blood cells\<4,000/mm³, platelets count\<100,000/mm³, hematocrit\<30% * Severe comorbidities (heart, renal, liver failure), autoimmune diseases or any type of interstitial lung disease * Patients who underwent non invasive ventilation, tracheotomy and /or gastrostomy * Women who are pregnant or breastfeeding * Participation in pharmacological studies within the last 30 days before screening * Patients with the following ALS phenotypes: flail arm, flail leg, UMN-p, respiratory, PLS, progressive muscular atrophy. * Patients with familial ALS defined as presence of at least one first degree family member (parents/son/daughter/brother/sister) affected by ALS. * Patients with known pathogenic mutations (SOD1, TARDBP, FUS, C9ORF72).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R) | comparison between baseline and treatment end (week 30) | ALSFRS-R is a scale that measures disability in ALS; the scores range from 0 (maximum disability, the worst score) to 48 (no disability, the best score). We will measure total score changes from baseline to week 30 in treatment and placebo arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tracheostomy-free survival rate | Up to week 54 | Overall survival from randomization to date of death or tracheostomy |
| Changes in Forced Vital Capacity (FVC) | Up to week 54 | Changes in FVC score from baseline to week 8, 18, 30, 54 in treatment and placebo arms. |
| Changes in quality of life | at 8,18,30 and 54 week | Changes in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) from baseline to week 8, 18, 30 and week 54, in placebo and treatment arms |
| enhancement of autophagy | at week 30 and 54, compared to baseline | assessment of mRNA and protein levels of p62, LC3, TFEB, ATGs, HSPB8, BAG3, BAG1, HSP70, and HSF1, in patients' PBMCs, lymphoblasts and fibroblasts (transcriptome profile); |
| Incidence of Treatment-Emergent Adverse Events (safety and tolerability) | week 30 and 54 | Number of serious adverse events (SAEs) and AEs in placebo and treatment arms |
| quantification of insoluble species | at week 30 compared to baseline | assessment of overall levels and the relative ratio between soluble and insoluble species of TDP-43, TDP-43 fragments, SQSTM1/p62, UBQLN, OPTN in fibroblasts and lymphoblasts derived from the same patients |
| modifications on extracellular vesicles secretion in blood and CSF | at week 30 compared to baseline | assessment of TDP-43, hyperphosphorylated TDP-43, SQSTM1/p62, UBQLN and OPTN in extracellular vesicles by plasma and CSF. |
| effects on biomarkers of neurodegeneration | at week 30 compared to baseline | creatinine, albumin, CK, and vitamin D in plasma as markers of disease severity; phosphorylated neurofilaments heavy chain |
| effects on biomarkers of inflammation | at week 30 compared to baseline | assessment of plasma/CSF IL18, its endogenous inhibitor IL-18BP, MCP1 and IL17 |
| changes in stress granules size, number and composition | at week 30 compared to baseline | identification of changes in stress granules response and composition in patients' fibroblasts and lymphoblasts will be carried out by measuring granules size, number and composition by confocal microscopy using automated systems. The aberrant recruitment or sequestration of specific mRNA inside stress granules will be assessed by FISH using specific probes, followed by densitometric analysis as previously described by Gareau et al. (2011). |
Countries
Italy
Outcome results
None listed